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Introduction: The prognosis of medullary thyroid carcinoma (MTC) is poor using 
common chemotherapeutic approaches. However, during the last years encouraging 
results of recently introduced tyrosine kinase inhibitors (TKI) such as vandetanib 
have been published. In this study we aimed to correlate the results of 18F-
fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging with 
treatment outcome. 
 
Methods: Eighteen patients after thyroidectomy with recurrent/advanced MTC 
lesions receiving vandetanib (300 mg orally/day) could be analysed. A baseline 18F-
FDG PET prior to and a follow-up 18F-FDG PET 3 months after TKI initiation were 
performed. During follow-up, tumor progression was assessed every 3 months 
including computed tomography according to RECIST. Progression-free survival 
(PFS) was correlated with the maximum standardized uptake value of 18F-FDG in 
lymph nodes (SUV(LN)max) or visceral metastases (SUV(MTS)max) as well as with 
clinical parameters using ROC analysis. 
 
Results: Within median 3.6 years of follow-up, 9 patients showed disease 
progression at median 8.5 months after TKI initiation. An elevated glucose 
consumption assessed by baseline 18F-FDG PET (SUV(LN)max > 7.25) could predict 
a shorter PFS (2 y) with an accuracy of 76.5% (SUV(LN)max <7.25, 4.3 y; p=0.03). 
Accordingly, preserved tumor metabolism in the follow-up PET (SUV(MTS)max >2.7) 
also demonstrated an unfavorable prognosis (accuracy, 85.7%). On the other hand, 
none of the clinical parameters reached significance in response prediction. 
 
Conclusions: In patients with advanced and progressive MTC, tumors with higher 
metabolic activity at baseline are more aggressive and more prone to progression as 
reflected by a shorter PFS; they should be monitored more closely. Preserved 
glucose consumption 3 months after treatment initiation was also related to poorer 
prognosis. 
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